BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

The collaboration includes a multisystem order planned for installation at IPMG clinics in Southern California.

Rhea-AI Summary

BrainsWay (BWAY) announced a collaboration with Inland Psychiatric Medical Group that includes an order for multiple Deep TMS systems. The systems are planned for installation at IPMG clinics in Southern California. The collaboration also includes exploring scientific, clinical and research projects aimed at expanding applications of interventional psychiatry and mental health care.

IPMG provides psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment and clinical research. BrainsWay’s Deep TMS, a treatment that uses magnetic pulses to stimulate brain networks, is currently FDA-cleared for major depressive disorder with and without anxiety symptoms, obsessive-compulsive disorder and smoking addiction.

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.Multisystem Deep TMS order includes planned installation at Inland Psychiatric Medical Group clinics.
• Minor point. Forward-looking: it has not happened yet and may not happen.Research collaboration includes exploring scientific and clinical projects to expand interventional psychiatry applications.

Negative

• None.

Key Terms

tms therapy, esketamine, fda-cleared, obsessive-compulsive disorder

4 terms

tms therapy medical

"psychiatry, medication management, psychotherapy, TMS therapy"

TMS therapy is a noninvasive medical treatment that uses a specialized coil placed against the scalp to generate brief magnetic pulses, which induce small electric currents in targeted brain regions to modulate neural activity. It is delivered in repeated outpatient sessions by trained clinicians using FDA-cleared or otherwise regulated devices and is commonly used for conditions like treatment-resistant depression and certain other neuropsychiatric disorders where regulatory authorities have approved the device for specific indications. The therapy is device-based rather than pharmacological, typically requires a course of multiple sessions, and its availability and approved uses depend on medical regulation in each jurisdiction.

esketamine medical

"TMS therapy, esketamine treatment, and clinical research"

A prescription medication that is the S-enantiomer of ketamine, used under medical supervision to treat severe, treatment-resistant depression and acute suicidal thoughts. Administered in controlled settings (often as a nasal spray or intravenous infusion), it acts quickly on brain chemistry compared with traditional antidepressants. It matters to investors because regulatory approvals, patent protection, pricing, and clinic access shape potential revenue, safety liability, and market adoption—similar to how a new, fast-acting tool can change demand in an established toolbox.

fda-cleared regulatory

"The system is currently FDA-cleared to treat major depressive disorder"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

obsessive-compulsive disorder medical

"obsessive-compulsive disorder (OCD), and smoking addiction"

Obsessive-compulsive disorder (OCD) is a mental health condition marked by unwanted, repetitive thoughts (obsessions) and time-consuming actions or rituals (compulsions) performed to ease anxiety. For investors, OCD matters because it influences demand for medical treatments, therapy services, and workplace accommodations, and can affect productivity, healthcare costs, and the commercial potential of drugs or devices aimed at managing the condition — much like how a chronic physical illness shapes markets and spending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic collaboration with Inland Psychiatric Medical Group (“IPMG”), an established provider of comprehensive behavioral health services across Southern California.

IPMG operates a multidisciplinary behavioral health practice serving patients throughout Southern California, including in Riverside, San Bernardino, Los Angeles, and Orange Counties. Its comprehensive clinical services include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research.

The collaboration with BrainsWay includes a multisystem order of BrainsWay Deep TMS systems planned for installation at IPMG clinics, and the exploration of a range of scientific, clinical and research projects designed to expand the possibilities of interventional psychiatry and mental health care for the benefit of patients and providers.

“We are proud to establish this partnership with IPMG as we explore ways to mutually advance our shared goal of improving patients’ lives through a variety of interventional psychiatry treatments,” said Hadar Levy, Chief Executive Officer of BrainsWay. “This cooperation serves to advance the interests of the patients we serve, and further reflects our strategy of building relationships with key accelerators of innovation in the mental health space.”

BrainsWay Deep TMS is an innovative therapy delivered through a patented and unique coil design which is housed within a cushioned, patient and provider-friendly helmet. By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system is capable of stimulating underactive neural networks. The system is currently FDA-cleared to treat major depressive disorder both with and without anxiety symptoms, obsessive-compulsive disorder (OCD), and smoking addiction.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “targets,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. It is important that the reader access the full publication via the link above in order to obtain more detail and context on the findings referenced herein. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BrainsWay’s collaboration with Inland Psychiatric Medical Group include?

The collaboration includes a multisystem order of Deep TMS systems planned for installation at IPMG clinics, alongside exploration of scientific, clinical and research projects in interventional psychiatry and mental health care.